Nitazoxanide in Patients With Ulcerative Colitis

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 30, 2025

Primary Completion Date

August 20, 2026

Study Completion Date

December 20, 2026

Conditions
Ulcerative Colitis
Interventions
DRUG

Mesalamine

Mesalamine or 5-amino salicylic acid (5-ASA), plays a crucial role in the treatment of ulcerative colitis (UC). It is the first-line therapy for mild to moderate cases of UC and is considered a cornerstone in its management.

DRUG

Nitazoxanide

Nitazoxanide is an FDA-approved oral medication used to treat protozoal infections and is also effective against metronidazole-resistant Clostridium difficile colitis.

Trial Locations (1)

Unknown

RECRUITING

Alexandria University, Alexandria

All Listed Sponsors
collaborator

Prof. Dr. Ahmed Ibrahim Mohammed El Mallah, faculty of pharmacy, Alexandria University.

UNKNOWN

collaborator

Assoc. Prof. Dr. Noha Alaa Eldin Hassan Hamdy, Faculty of pharmacy, Alexandria University.

UNKNOWN

collaborator

Assoc. Prof. Dr. Ibrahim Fathi Amer, Faculty of Medecine, Kafr Elsheikh University.

UNKNOWN

lead

Alexandria University

OTHER

NCT06993974 - Nitazoxanide in Patients With Ulcerative Colitis | Biotech Hunter | Biotech Hunter